Key result
Cardiac troponin has replaced creatine kinase MB as the gold standard for diagnosing myocardial infarction, with emerging markers offering potential for risk stratification and identifying vulnerable plaques.
This review summarizes the evolution of biochemical markers in acute coronary syndrome, emphasizing cardiac troponin as the diagnostic gold standard and highlighting future markers for risk stratification.
Answers are grounded in this paper and cite their sources.
Troponin remains the MI diagnostic standard; leaves open whether emerging markers improve risk stratification or plaque detection.
The use of biochemical markers in the diagnosis and management of patients with acute coronary syndrome has increased continually in recent decades. The development of highly sensitive and cardiac-specific troponin assays has changed the view on diagnosis of myocardial infarction and also extended the role of biochemical markers of necrosis into risk stratification and guidance for treatment. The consensus definition of myocardial infarction places increased emphasis on cardiac marker testing, with cardiac troponin replacing creatine kinase MB as the "gold standard" for diagnosis of myocardial infarction. Along with advances in the use of more cardiac-specific markers of myocardial necrosis, biochemical markers that are involved in the progression of atherosclerotic plaques to the vulnerable state or that signal the presence of vulnerable plaques have recently been identified. These markers have variable abilities to predict the risk of an individual for acute coronary syndrome. The aim of this review is to provide an overview of the well-established markers of myocardial necrosis, with a special focus on cardiac troponin I, together with a summary of some of the potential future markers of inflammation, plaque instability, and ischemia.
No takes yet. Share an insight, caveat, or question.
Eriksson et al. (2006) conducted a review in Acute coronary syndrome. Biochemical markers was evaluated. Cardiac troponin has replaced creatine kinase MB as the gold standard for diagnosing myocardial infarction, with emerging markers offering potential for risk stratification and identifying vulnerable plaques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: